These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8105307)

  • 1. Sampling and sensing blood glucose.
    Pickup JC
    Lancet; 1993 Oct; 342(8879):1068. PubMed ID: 8105307
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term continuous glucose monitoring with microdialysis in ambulatory insulin-dependent diabetic patients.
    Bolinder J; Ungerstedt U; Arner P
    Lancet; 1993 Oct; 342(8879):1080-5. PubMed ID: 8105311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-monitoring with continuous subcutaneous microdialysis in neonatal diabetes mellitus.
    Baumeister FA; Hack A; Busch R
    Klin Padiatr; 2006; 218(4):230-2. PubMed ID: 16819705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous microdialysis before and after an oral glucose tolerance test: a method to determine insulin resistance in the subcutaneous adipose tissue in diabetes mellitus.
    Rajamand N; Ungerstedt U; Brismar K
    Diabetes Obes Metab; 2005 Sep; 7(5):525-35. PubMed ID: 16050945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin action in insulin-dependent diabetes mellitus (type I): measurement during constant and changing insulin concentrations.
    Doeden B; Rizza R
    J Lab Clin Med; 1988 Jul; 112(1):28-35. PubMed ID: 3292681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of insulin pumps for diabetes management.
    Webb KE
    Medsurg Nurs; 2006 Apr; 15(2):61-8, 94; quiz 69. PubMed ID: 16700243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue IGF-I Measured by Microdialysis Reflects Body Glucose Utilization After rhIGF-I Injection in Type 1 Diabetes.
    Ekström K; Pulkkinen MA; Carlsson-Skwirut C; Brorsson AL; Ma Z; Frystyk J; Bang P
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4299-306. PubMed ID: 26331550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients.
    Wentholt IM; Vollebregt MA; Hart AA; Hoekstra JB; DeVries JH
    Diabetes Care; 2005 Dec; 28(12):2871-6. PubMed ID: 16306547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of meals with different glycaemic index on postprandial blood glucose response in patients with Type 1 diabetes treated with continuous subcutaneous insulin infusion.
    Parillo M; Annuzzi G; Rivellese AA; Bozzetto L; Alessandrini R; Riccardi G; Capaldo B
    Diabet Med; 2011 Feb; 28(2):227-9. PubMed ID: 21219435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The dawn phenomenon could be due to nictemeral rhythms in the peripheral metabolism of insulin].
    Levy I; Bergua M; Recasens A; Gutiérrez A; Rodríguez MD; Vidal N; Capillas R; Goday A; Casamitjana R; Guillén M
    Med Clin (Barc); 1986 May; 87(1):6-9. PubMed ID: 3736203
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dawn phenomenon].
    Corcos AP; Friedmann R; Lysy Y; Chowers I
    Harefuah; 1986 Nov; 111(10):295-9. PubMed ID: 3817616
    [No Abstract]   [Full Text] [Related]  

  • 12. Variability of blood glucose levels in patients with type 1 diabetes mellitus on intensified insulin regimens.
    Moberg EA; Lins PE; Adamson UK
    Diabete Metab; 1994; 20(6):546-52. PubMed ID: 7713278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rise at dawn. Why does blood glucose spike in the a.m.?
    Gebel E
    Diabetes Forecast; 2012 Mar; 65(3):28, 30. PubMed ID: 22439376
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous continuous glucose monitoring: feasibility of a new microdialysis-based glucose sensor system.
    Jungheim K; Wientjes KJ; Heinemann L; Lodwig V; Koschinsky T; Schoonen AJ;
    Diabetes Care; 2001 Sep; 24(9):1696-7. PubMed ID: 11522729
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on Kramer et al. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. Diabetes Care 2014;37:1076-1082.
    Takahashi N; Tsujimoto T; Kajio H
    Diabetes Care; 2014 Oct; 37(10):e224. PubMed ID: 25249684
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment on Kramer et al. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. Diabetes Care 2014;37:1076-1082.
    Ali S; Kuhadiya N; Ghanim H; Chaudhuri A
    Diabetes Care; 2014 Sep; 37(9):e208. PubMed ID: 25147268
    [No Abstract]   [Full Text] [Related]  

  • 17. Oxidative stress is, convincingly, the mediator of the dangerous effects of glucose variability.
    Ceriello A; Ihnat M
    Diabet Med; 2010 Aug; 27(8):968. PubMed ID: 20653758
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to comment on Kramer et al. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. Diabetes Care 2014;37:1076-1082.
    Kramer CK; Retnakaran R; Zinman B
    Diabetes Care; 2014 Sep; 37(9):e209. PubMed ID: 25147269
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to comment on Kramer et al. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. Diabetes Care 2014;37:1076-1082.
    Kramer CK; Retnakaran R; Zinman B
    Diabetes Care; 2014 Oct; 37(10):e225. PubMed ID: 25249685
    [No Abstract]   [Full Text] [Related]  

  • 20. Insulin resistance in multiple tissues in patients with type 1 diabetes mellitus on long-term continuous subcutaneous insulin infusion therapy.
    Donga E; van Dijk M; Hoogma RP; Corssmit EP; Romijn JA
    Diabetes Metab Res Rev; 2013 Jan; 29(1):33-8. PubMed ID: 22936679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.